MOUNTAIN VIEW, Calif. (May 7, 2007) – At the annual clinical meeting of the American College of Obstetricians and Gynecologists (ACOG) underway in San Diego, Conceptus, Inc. (NASDAQ: CPTS) is celebrating five years of U.S. commercial sales of the Essure® procedure, the first and only permanent birth control that does not require surgery. Last month Conceptus announced that more than 115,000 women worldwide had undergone the procedure, which is a far less invasive solution to tubal ligation.

More physicians are recommending and more women are choosing Essure because the procedure can be done quickly and conveniently in a physician’s office with minimal anesthesia, and requires very little patient recovery time. Several thousand physicians have performed the Essure procedure and nearly 2,000 physicians adopted the technology last year alone.

Approximately 36 percent of the Essure procedures are now being performed in physician offices under minimal anesthesia. The Essure procedure takes about 10 minutes is easy to perform and does not involve the burning or scarring of the Fallopian tubes, which can contribute to significant pain and a longer recovery. Studies show that with the Essure procedure, women experience very little discomfort, often less than what is experienced during monthly menstrual cramps. The Essure device is 99.80 percent effective at 4 years of follow-up, with zero pregnancies reported in clinical studies.

All major private payers and Medicaid programs in 43 states are covering the Essure procedure. “We’re proud to say that the Essure procedure is a covered benefit for 93 percent of women in the United States,” said Mark Sieczkarek, president and chief executive officer of Conceptus. “With Essure everyone wins, including payers who have a proven procedure performed on an outpatient basis, physicians who face favorable economics when performing the procedure especially in an office setting, and the patient who has a minimally invasive option with comparatively very quick recovery time. We have made major strides with payers and physician adoption, and are extremely proud of our long-term clinical data, which is strengthening by the day. Conceptus is increasingly becoming known as a leader in women’s healthcare.”

The company was recently named as the fourth fastest growing medical equipment company in the Deloitte Technology Fast 500 program, and MSN money reports “the company is uniquely positioned in the female contraception market as it has the only FDA approved permanent birth control device on the market.”

On April 30, 2007 Conceptus announced first quarter 2007 revenues of $13.8 million, an increase of 73 percent over the same period last year, and affirmed that it is on track to reach profitability in the fourth quarter of 2007.

About the Essure Procedure

The Essure procedure, approved by the FDA in 2002, is a sterilization procedure that replaces tubal ligation for women. A soft micro-insert is placed into the Fallopian tubes through the cervix using a hysteroscope. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the Fallopian tubes, over three months. An Essure procedure does not require cutting into the body and can be performed in the doctor’s office, a less costly procedure setting, with just a local anesthetic. A woman is able to leave the office about 45 minutes after the procedure is completed. The Essure confirmation test is performed three months after the procedure to confirm that the micro-inserts are in the correct location, the tubes are blocked and that the woman can discontinue temporary birth control. The Essure procedure is 99.80% effective (based on four years of clinical study follow-up data). The probability of pregnancy in 1000 women at 4 years is only 2.0 as compared to 11.8 for surgical tubal ligation procedures studied in CREST.

About Conceptus

Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide. The availability of the Essure procedure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually.

Additional information about the Essure procedure is available at www.essure.com or by calling the Essure Information Center at 1-877-ESSURE1. Additional information about Conceptus is available at www.conceptus.com or by calling 1-877-ESSURE2.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Discussions regarding growth in net sales and the sales force, expected profitability, guidance and cash flow information, physician utilization and the performance of Essure in the office setting, and other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors such as strategic planning decisions by management, re-allocation of internal resources, decisions by insurance companies, scientific advances by third parties, and introduction of competitive products, as well as those factors set forth in the Company's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, and other filings with the Securities and Exchange Commission.